Becton Dickinson, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on the stock and has a $196.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Wood has given his Buy rating due to a combination of factors that highlight Becton Dickinson’s strong performance and potential for future growth. The company’s recent financial results exceeded expectations, with organic growth slightly surpassing market predictions. This was complemented by a solid performance across various segments, notably in Interventional and Medical, which contributed to the overall positive outlook.
Moreover, Becton Dickinson’s ability to maintain cost control and improve operating margins has led to an adjusted EPS that was significantly higher than consensus estimates. The company’s strategic initiatives, including the upcoming RMT with Waters and a focus on cash returns to shareholders, further enhance its mid-term value proposition. These elements collectively support a positive investment thesis, justifying the Buy rating.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $216.00 price target.
BDX’s price has also changed moderately for the past six months – from $229.850 to $187.680, which is a -18.35% drop .